HLS Therapeutics Inc Stock Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 86.97M 74.93M 70.95M 64.31M 121M 8.31B 121M 843M 324M 4.23B 327M 319M 13.36B | P/E 2026 * |
-13.6x | P/E 2027 * | -40.2x |
|---|---|---|---|---|---|
| Enterprise Value | 86.97M 74.93M 70.95M 64.31M 121M 8.31B 121M 843M 324M 4.23B 327M 319M 13.36B | EV / Sales 2026 * |
1.49x | EV / Sales 2027 * | 1.34x |
| Free-Float |
99.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 2023-04-30 |
John Hanna
DFI | Director of Finance/CFO | 61 | 2024-01-25 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 2014-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 2018-03-11 |
John Welborn
CHM | Chairman | 48 | 2023-06-21 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 2020-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 86.97M | |
| +0.07% | -2.92% | +23.91% | +108.84% | 103B | |
| -0.61% | -5.10% | +54.08% | +163.77% | 54.56B | |
| -0.38% | -2.59% | -12.33% | +250.67% | 21.7B | |
| -0.12% | -1.99% | -9.55% | -9.40% | 8.07B | |
| -1.35% | -4.06% | -38.80% | -33.95% | 6.86B | |
| +0.59% | +0.68% | +3.79% | +30.88% | 6.82B | |
| -0.90% | -2.10% | -19.79% | -30.81% | 6.11B | |
| +0.30% | +0.06% | -5.31% | +20.13% | 5.07B | |
| -10.00% | +1.12% | +344.99% | +500.50% | 4.6B | |
| Average | -1.24% | -1.76% | +37.89% | +111.18% | 24.06B | |
| Weighted average by Cap. | -0.42% | -3.11% | +28.91% | +127.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.44M 50.35M 47.68M 43.21M 81.07M 5.58B 81.48M 566M 218M 2.84B 219M 215M 8.98B | 65.03M 56.03M 53.05M 48.08M 90.21M 6.21B 90.66M 630M 242M 3.16B 244M 239M 9.99B |
| Net income | -5.47M -4.71M -4.46M -4.04M -7.59M -523M -7.63M -53M -20.38M -266M -20.54M -20.09M -840M | -2.16M -1.86M -1.77M -1.6M -3M -207M -3.02M -20.97M -8.06M -105M -8.13M -7.95M -332M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
